Dragons Exalted #14/124
Catalog details are community-maintained and may be incomplete. Confirm the printing in seller photographs before buying.
Collection-interest profile, not a price, appraisal, or promise of profit.
TCGdex identifies this printing as Uncommon. The score follows Diamond Finder's published V1 rarity ladder; it does not measure price or scarcity.
This character does not receive an enhanced editorial weighting in the current V1 list. That does not mean the card lacks fans or value.
Dragons Exalted currently uses the neutral V1 set baseline because Diamond Finder has not added a special editorial flag for it.
This factor uses only the set release year. Older does not automatically mean rarer, more valuable, or a better purchase.
The catalog records 1 known printing option: normal. This is a same-card variant signal only; future reprints are unknown.
This summary combines the published rarity and character factors. It is not an appraisal or prediction.
These are transparent learning signals, not a promise that the card will rise in value.
TCGplayer currently provides a market price for Reverse Holofoil of about $1.34. Treat it as a live reference, not a guaranteed sale price or appraisal.
Marketplace references can be missing or imperfectly matched to a printing or variant. Confirm the exact card, finish, condition, language, and recent real-world sales before making a purchase decision.
Cardmarket rolling averages supplied with this exact catalog record. These are market references, not guaranteed sold prices.
Your collection and Want List are account-scoped and stay blank while you are signed out.
Move from this printing into the same character, set, era, or rarity—without starting another blind search.
Instead of a generic compound-interest calculator, this model starts with the exact card's current market reference, short-term market trend, and Diamond Finder Collector Index.
MARKET OUTLOOK FORRoseradeDragons Exalted · #14/124Model estimate, not a guaranteed future value. It does not use eBay sold comps yet, and no projection should be treated as investment advice.